91 related articles for article (PubMed ID: 26111725)
1. Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment.
Ferguson SA; Law CD; Sarkar S
Behav Brain Res; 2015 Oct; 292():68-78. PubMed ID: 26111725
[TBL] [Abstract][Full Text] [Related]
2. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
4. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
5. Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Pothakos K; Kurz MJ; Lau YS
BMC Neurosci; 2009 Jan; 10():6. PubMed ID: 19154608
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.
Patil SP; Jain PD; Ghumatkar PJ; Tambe R; Sathaye S
Neuroscience; 2014 Sep; 277():747-54. PubMed ID: 25108167
[TBL] [Abstract][Full Text] [Related]
7. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
Fifel K; Dkhissi-Benyahya O; Cooper HM
Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
[TBL] [Abstract][Full Text] [Related]
8. The MPTP/probenecid model of progressive Parkinson's disease.
Carta AR; Carboni E; Spiga S
Methods Mol Biol; 2013; 964():295-308. PubMed ID: 23296790
[TBL] [Abstract][Full Text] [Related]
9. Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson's disease.
Rekha KR; Selvakumar GP
Chem Biol Interact; 2014 Jun; 217():57-66. PubMed ID: 24768735
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
11. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease.
Luchtman DW; Meng Q; Song C
Behav Brain Res; 2012 Jan; 226(2):386-96. PubMed ID: 21971013
[TBL] [Abstract][Full Text] [Related]
12. Consequences of manganese administration for striatal dopamine and motor behavior in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed C57BL/6 mice.
Dodd CA; Bloomquist JR; Klein BG
Hum Exp Toxicol; 2013 Aug; 32(8):865-80. PubMed ID: 23263854
[TBL] [Abstract][Full Text] [Related]
13. Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Schumm S; Sebban C; Cohen-Salmon C; Callebert J; Launay JM; Golmard JL; Boussicault L; Petropoulos I; Hild A; Rousselet E; Prigent A; Friguet B; Mariani J; Hirsch EC
J Neurochem; 2012 Sep; 122(5):1032-46. PubMed ID: 22708926
[TBL] [Abstract][Full Text] [Related]
14. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
15. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
Luchtman DW; Shao D; Song C
Physiol Behav; 2009 Aug; 98(1-2):130-8. PubMed ID: 19410592
[TBL] [Abstract][Full Text] [Related]
16. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
17. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease.
Geng X; Tian X; Tu P; Pu X
Eur J Pharmacol; 2007 Jun; 564(1-3):66-74. PubMed ID: 17359968
[TBL] [Abstract][Full Text] [Related]
19. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
Fredriksson A; Archer T
Behav Brain Res; 2003 Feb; 139(1-2):31-46. PubMed ID: 12642174
[TBL] [Abstract][Full Text] [Related]
20. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
